Kiniksa Pharmaceuticals International (KNSA) Current Assets (2017 - 2026)

Kiniksa Pharmaceuticals International's Current Assets history runs 10 years deep, the most recent figure standing at $594.2 million for Q1 2026.

• Quarterly Current Assets rose 66.95% year-over-year to $594.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $594.2 million (up 66.95% YoY) and the FY2025 annual result came in at $527.2 million, up 58.88% from the prior year.
• Current Assets was $594.2 million for Q1 2026 at Kiniksa Pharmaceuticals International, up from $527.2 million in the prior quarter.
• Across five years, Current Assets topped out at $594.2 million in Q1 2026 and bottomed at $179.9 million in Q2 2022.
• A 5-year average of $321.3 million and a median of $276.3 million in 2023 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets declined 27.87% — and 2026, when it soared 66.95%.
• Kiniksa Pharmaceuticals International's Current Assets stood at $243.1 million in 2022, then rose by 13.67% to $276.3 million in 2023, then gained by 20.09% to $331.8 million in 2024, then surged by 58.88% to $527.2 million in 2025, then rose by 12.71% to $594.2 million in 2026.
• Business Quant data shows KNSA's Current Assets at $594.2 million in Q1 2026, $527.2 million in Q4 2025, and $475.5 million in Q3 2025.